Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cognition Therapeutics, Inc.

< Previous 1 2 Next >
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics CEO Issues Letter to Shareholders
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Participation in Upcoming September Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.